[A Case Report of Successful Treatment with Dose-controlled mFOFOX6+Bevacizumab for Metastatic Colorectal Cancer in Patient Receiving Hemodialysis].
Ayumi OzekiHideya KokubunSho IbukiMasayuki InamotoYoshihiko SakuraiTakahiro OtaniJunya SatoPublished in: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan (2024)
A 65-years-old man undergoing hemodialysis for chronic kidney disease was diagnosed with ascending colon cancer and 3 hepatic metastases. He was administered mFOLFOX6 (reducing the dose to 50%) plus bevacizumab (BEV) therapy. Hemodialysis was performed 4 h after administration of oxaliplatin on day1 and repeated three times a week. No serious adverse events were observed. After 4 courses of chemotherapy, a computer tomography scan showed that the hepatic metastases had reduced. 2 courses of mFOLFOX6 (increasing the dose to 75%) plus BEV therapy were added, he was operated by laparoscopic right hemicolectomy and laparoscopic patrial hepatectomy. He has been in remission for 2 years and 4 months since the surgery. Dose-adjusted chemotherapy with hemodialysis was effective and improve the prognosis of the patient.
Keyphrases
- metastatic colorectal cancer
- chronic kidney disease
- end stage renal disease
- peritoneal dialysis
- case report
- robot assisted
- minimally invasive
- locally advanced
- squamous cell carcinoma
- randomized controlled trial
- clinical trial
- atrial fibrillation
- bone marrow
- stem cells
- systemic lupus erythematosus
- pulmonary arterial hypertension
- coronary artery disease
- pulmonary hypertension
- cell therapy
- acute coronary syndrome
- percutaneous coronary intervention